The Role of Inflammation in Atherosclerosis

ABSTRACT

The evolving literature clearly indicates that atherosclerosis represents a chronic inflammatory process that increases the risk for intraluminal thrombosis and incidence of ischemic stroke and heart attack. The understanding of the immune system's role in the pathophysiology of atherosclerosis will help to modify our utilization of medications that minimize the influence of the inflammatory character of the plaque and potentially reduce the risk of plaque destabilization and thromboembolic events. Recognition of biological markers and susceptibility genes will further improve the ability to predict the at-risk population and target susceptible patient populations to early interventional therapeutic modalities.

KEYWORDS

Atherosclerosis - inflammation - infection - therapy - C-reactive protein - T-lymphocytes

REFERENCES

• 1 Gillum R F, Sempas C T. The end of the long-term decline in stroke mortality in the United States?.  Stroke . 1997;  28 1527-1529
• 2 North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.  N Engl J Med . 1991;  325 445-453
• 3 Toole J F, on behalf of the ACAS Executive Committee. ACAS recommendations for carotid endarterectomy.  Lancet . 1996;  347 121
• 4 Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization.  Am J Cardiol . 2000;  86 3J-9J
• 5 Benveniste E N. Inflammatory cytokines within the central nervous system: source, function, and mechanism of action.  Am J Physiol . 1992;  263 C1-16
• 6 Hallenbeck J M. Inflammatory reactions at the blood-endothelial interface in acute stroke.  Adv Neurol . 1996;  71 281-300
• 7 Rothwell N J, Loddick S A, Stroemer P. Interleukins and cerebral ischemia.  Int Rev Neurobiol . 1997;  40 281-298
• 8 Bevilacqua M P, Pober J S, Majeau G R, Cotran R S, Gimbrone Jr A R. Interleukin-1 (IL-1) induces biosynthesis and cell surface expression of pro-coagulant activity in human vascular endothelial cells.  J Exp Med . 1984;  160 618-623
• 9 Nawroth P P, Handley D A, Esmon C T, Stern D M. Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity.  Proc Natl Acad Sci USA . 1986;  83 3460-3464
• 10 Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.  J Exp Med . 1986;  163 740-745
• 11 DeGraba T J, Sirén A-L, Penix L. et al . Increased endothelial expression of intercellular adhesion molecule-1 (ICAM-1) in symptomatic vs asymptomatic human atherosclerotic plaque.  Stroke . 1998;  29 1405-1410
• 12 Jander S, Sitzer M, Schumann R. et al . Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization.  Stroke . 1998;  29 1625-1630
• 13 van der Wal C A, Becker A E, van de Loos M C, Das P K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology.  Circulation . 1994;  89 36-44
• 14 Morigi M, Zoja C, Figliuzzi M. et al . Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells.  Blood . 1995;  85 1696-1703
• 15 Malek A M, Jackman R, Rosenberg R D, Izumo S. Endothelial expression of thrombomodulin is reversibly regulated by fluid shear stress.  Circ Res . 1994;  74 852-860
• 16 Steinberg D, Parthasarathy S, Carew T E, Khoo J C, Witztum J L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity.  N Engl J Med . 1989;  320 915-924
• 17 Stemme S, Faber B, Holm J, Wiklund O, Witztum J L, Hansson G K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein.  Proc Natl Acad Sci USA . 1995;  92 3893-3897
• 18 Zhu B, Sun Y, Sievers R E, Isenberg W M, Glantz S A, Parmelye W W. Passive smoking increases experimental atherosclerosis in cholesterol-fed rabbits.  J Am Coll Cardiol . 1993;  21 225-232
• 19 Miller G J, Bauer K A, Cooper J A, Rosenberg R D. Activation of the coagulant pathway in cigarette smokers.  Thromb Haemost . 1998;  79 549-553
• 20 Newby D E, Wright R A, Labinjoh C. et al . Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking.  Circulation . 1999;  99 1411-1415
• 21 Zidovetzki R, Chen P, Fisher M, Hofman F M. Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway.  Stroke . 1999;  30 651-655
• 22 Markovitz J H, Tolbert L, Winders S E. Increased serotonin receptor density and platelet GPIIb/IIIa activation among smokers.  Arterioscler Thromb Vasc Biol . 1999;  19 762-766
• 23 Matetzky S, Tani S, Kangavari S. et al . Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity.  Circulation . 2000;  102 602-604
• 24 Celermajer D S, Adams M R, Clarkson P. et al . Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults.  N Engl J Med . 1996;  334 150-154
• 25 Hutchison S J, Sudhir K, Sievers R E. et al . Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke.  Hypertension . 1999;  34 44-50
• 26 Benowitz N L, Fitzgerald G A, Wilson M, Zhang Q. Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking.  J Am Coll Cardiol . 1993;  22 1159-1167
• 27 Patiño R, Ibarra J, Rodriguez A. et al . Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression.  Am J Cardiol . 2000;  85 1288-1291
• 28 Marfella R, Esposito K, Giunta R. et al . Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.  Circulation . 2000;  101 2247-2251
• 29 The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med . 2000;  342 145-153
• 30 Fukuhara M, Geary R L, Diz D I. et al . Angiotensin-converting enzyme expression in human carotid artery atherosclerosis.  Hypertension . 2000;  35[part 2] 353-359
• 31 Dzau V J. Mechanism of protective effects of ACE inhibition on coronary artery disease.  Eur Heart J . 1998;  19 (suppl J) J2-J6
• 32 Andersen S, Schalkwijk C G, Stehouwer R CD, Parving H H. Angiotensin-II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy.  Diabetes Care. 2000;  23 1031-1032
• 33 Fitzgerald J D. By what means might beta-blockers prolong life after acute myocardial infarction?.  Eur Heart J. 1987;  3 945-951
• 34 Scandinavian Simvastatin Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).  Lancet . 1994;  344 1383-1389
• 35 Sacks F M, Pfeffer M A, Moye L A, for the Recurrent Events Trial Investigators. et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.  N Engl J Med . 1996;  335 1001-1009
• 36 Ridker P M, Rifai N, Pfeffer M A. et al . Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1998;  98 839-844
• 37 Romano M, Diomede L, Sironi M. et al . Inhibition of monocyte chemotactic protein-1 synthesis by statins.  Lab Invest . 2000;  80 1095-1100
• 38 Bustos C, Hernandez-Presa M A, Orgego M. et al . HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.  J Am Coll Cardiol . 1998;  32 2057-2064
• 39 Kothe H, Dalhoff K, Rupp J. et al . Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae Circulation .  2000;  101 1760-1763
• 40 Vaughan C J, Gotto Jr M A, Basson C T. The evolving role of statins in the management of atherosclerosis.  J Am Coll Cardiol . 2000;  35 1-10
• 41 Crisby J, Nordin-Fredriksson G, Shah P K, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques.  Circulation . 2001;  103 926-933
• 42 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1999;  100 230-235
• 43 Hackam D G, Peterson J C, Spence J D. What level of plasma homocyst(e)ine should be treated?: Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 μmol/L.  Am J Hypertens. 2000;  13 105-110
• 44 Woodside J V, Yarnell J W, McMaster D. et al . Effect of B-group vitamins and antioxidant vitamins on hyperhomocystinemia: a double-blind, randomized, factorial-design, controlled trial.  Am J Clin Nutr. 1998;  67 858-866
• 45 Spence J D, Howard V J, Chambless L E. et al . Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.  Neuroepidemiology . 2001;  20 16-25
• 46 Gerhard G T, Duell P B. Homocysteine and atherosclerosis.  Curr Opin Lipidol . 1999;  10 417-428
• 47 Liao K, Yin M. Individual and combined antioxidant effects of seven phenolic agents in human erythrocyte membrane ghosts and phosphatidylcholine liposome systems: importance of the partition coefficient.  J Agric Food Chem . 2000;  48 2266-2270
• 48 Hamilton I MJ, Gilmore W S, Benzie I FF, Mulholland C W, Strain J J. Interactions between vitamins C and E in human subjects.  Br J Nutr . 2000;  84 261-267
• 49 Carretro O A, Miyazaki S, Scidli A G. Role of kinins in the acute anti-hypertensive effect of converting enzyme inhibitor, Captopril.  Hypertension . 1985;  3 8-22
• 50 Baur L H, Schipperheyn J J, van der Laarse A. et al . Combining salicylate and enalapril in patients with coronary artery disease and heart failure.  Br Heart J . 1995;  73 227-236
• 51 van Wijngaarden J, Smit A J, de Graeff A P. et al . Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.  J Cardiovasc Pharmacol . 1994;  23 240-245
• 52 Weksler B B, Pett S B, Alonso D. et al . Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.  N Engl J Med. 1983;  308(14) 800-805
• 53 Katz S D, Radin M, Graves T, Hauck C, Block A, LeJemtel T H. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with Enalapril. Ifetroban Study Group.  J Am Coll Cardiol. 1999;  34 170-176
• 54 Catella-Lawson F, Reilly M P, Kapoor S C. et al . Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.  N Engl J Med . 2001;  345 1809-1817
• 55 Ouellet M, Riendeau D, Percival M D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.  Proc Natl Acad Sci USA . 2001;  98 14583-14588
• 56 Mukherjee D, Nissen S E, Topol E EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors.  JAMA . 2001;  286 954-959
• 57 White W B, Faich G, Whelton A. et al . Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.  Am J Cardiol . 2002;  89 425-430
• 58 Tataru M C, Heinrich J, Junker R. et al . C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris.  Eur Heart J . 2000;  21 1000-1008
• 59 Rohde L E, Lee R T, Rivero J. et al . Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis.  Arterioscler Thromb Vasc Biol . 1998;  18 1765-1770
• 60 Ridker P M, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.  Circulation . 2000;  101 2149-2153
• 61 Hwang S J, Ballantyne C M, Sharrett A R. et al . Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the atherosclerosis risk in communities (ARIC) study.  Circulation . 1997;  96 4219-4225
• 62 Ridker P M. High sensitivity C-reactive protein.  Circulation . 2001;  103 1813-1818
• 63 Ridker P M, Cushman M, Stanpfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med . 1997;  336 973-979
• 64 Downs J R, Clearfield M, Weis S. et al . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.  JAMA . 1998;  279 1615-1622
• 65 Pasceri V, Chang J, Willerson J T, Yeh E TH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.  Circulation . 2001;  103 2531-2534
• 66 Ridker P M, Rifai N, Pfeffer M A, Sacks F, Braunwald E, for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators.  Circulation . 1999;  100 230-235
• 67 Ridker P M, Cushman M, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.  N Engl J Med . 1997;  336 973-979
• 68 Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.  Int J Cardiol . 2001;  77 247-253
• 69 Morris M S, Jacques P F, Rosenberg I H. et al . Serum total homocysteine concentration is related to self-reported heart attack or stroke history among men and women in the NHANES III.  J Nutr . 2000;  130 3073-3076
• 70 Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and re-stenosis: an assessment of the evidence and need for future research.  Circulation . 1997;  96 4095-4103
• 71 Epstein S E, Zhou Y F, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms.  Circulation . 1999;  100 E20-E28
• 72 Vercellotti G. Infectious agents that play a role in atherosclerosis and vasculopathies: what are they?.  <~>What do we do about them? Can J Cardiol . 1999;  15 (suppl B) 13B-15B
• 73 Nieto F J, Adam E, Sorlie P. et al . Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis.  Circulation . 1996;  94 922-927
• 74 Sorlie P D, Adam E, Melnick S L. et al . Cytomegalovirus/ herpes virus and carotid atherosclerosis: the ARIC Study.  J Med Virol . 1994;  42 33-37
• 75 Whincup P H, Mendall M A, Perry I J, Strachan D P, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle-aged men.  Heart . 1996;  75 568-572
• 76 Patel P, Mendall M A, Carrington D. et al . Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors.  BMJ . 1995;  311 711-714
• 77 Ponzetto A, La Rovere T M, Sanseverino P, Bazzoli F. Association of Helicobacter pylori with coronary heart disease: study confirms previous findings.  BMJ . 1996;  312 251
• 78 Beck J, Garcia R, Heiss G, Vokonas P S, Offenbacher S. Periodontal disease and cardiovascular disease.  J Periodontol . 1996;  67 1123-1137
• 79 Span A H, vam Dam-Mieras C M, Mullers W, Endert J, Muller A D, Bruggeman C A. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells.  Eur J Clin Invest . 1991;  21 331-338
• 80 Hajjar D P. Viral pathogenesis of atherosclerosis.  Am J Path . 1991;  139 1195-1211
• 81 Minick C R, Fabricant C G, Fabricant J, Litrenta M M. Atheroarteriosclerosis induced by infection with a herpes virus.  Am J Path . 1979;  96 673-700
• 82 Benditt E P, Barrett T, McDougall J K. Viruses in the etiology of atherosclerosis.  Proc Natl Acad Sci USA . 1983;  80 6386-6389
• 83 Melnick J L, Adam E, Debakey M E. Possible role of cytomegalovirus in atherogenesis.  JAMA . 1990;  263 2204-2207
• 84 Zhu J, Quyyumi A A, Norman J E, Csako G, Epstein S E. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels.  J Am Coll Cardiol . 1999;  34 1738-1743
• 85 Ridker P M, Hennekens C H, Stampfer M J, Wang F. Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke.  Circulation . 1998;  98 2796-2799
• 86 Ridker P M, Hennekens C H, Roitman-Johnson B, Stampfer M J, Allen J. Plasma concentration of soluble ICAM-1 and risk of future myocardial infarction in apparently healthy men.  Lancet . 1998;  351 88-92
• 87 Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease.  Stroke . 1999;  30 299-305
• 88 Speir E, Modali R, Huang E S. et al . Potential role of human cytomegalovirus and p53 interaction in coronary restenosis.  Science . 1994;  265 391-394
• 89 Zhou Y F, Leon M B, Waclawiw M A. et al . Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy.  N Engl J Med . 1996;  335 624-630
• 90 Hendricks M G, Salimans M M, van Boven P C, Bruggeman C A. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis.  Am J Pathol . 1990;  136 23-28
• 91 Lemstrom K B, Aho P T, Bruggeman C A, Hayry P J. Cytomegalovirus infection enhances mRNA expression of platelet-derived growth factor-BB and transforming growth factor-beta 1 in rat aortic allografts: possible mechanism for cytomegalovirus-enhanced graft arteriosclerosis.  Arterioscler Thromb . 1994;  14 2043-2052
• 92 Geist L J, Monick M M, Stinski M F, Hunninghake G W. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-alpha gene expression.  J Clin Invest . 1994;  93 474-478
• 93 Kowalik T F, Wing B, Haskill J S, Azizkhan J C, Baldwin A S, Huang E S. Multiple mechanisms are implicated in the regulation of NF-B activity during human cytomegalovirus infection.  Proc Natl Acad Sci USA . 1993;  90 1107-1111
• 94 Van Dam-Mieras C E M, Muller A D, van Hinsbergh W M V, Mullers W H A J, Bomans P HH, Bruggeman C A. The procoagulant response of cytomegalovirus infected endothelial cells.  Thromb Haemost . 1992;  68 364-370
• 95 Eingen O R, Silverstein R L, Friedman H M, Hajjar D P. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells.  Cell . 1990;  61 657-662
• 96 Pryzdial E LG, Wright J F. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid.  Blood . 1994;  84 3749-3757
• 97 Span A H, vam Dam-Mieras C M, Mullers W, Endert J, Muller A D, Bruggeman C A. The effect of virus infection on the adherence of leukocytes or platelets to endothelial cells.  Eur J Clin Invest . 1991;  21 331-338
• 98 Grundy J E, Downes K L. Up-regulation of LFA-3 and ICAM-1 of the surface of fibroblasts infected with cytomegalovirus.  Immunology . 1993;  78 405-412
• 99 Span A H, Mullers W, Miltenberg A M, Bruggeman C A. Cytomegalovirus induced PMN adherence in relation to an ELAM-1 antigen present on infected endothelial cell monolayers.  Immunology . 1991;  72 355-360
• 100 LaBiche R, Koziol D, Quinn T. et al . Presence of Chlamydia pneumoniae in human symptomatic and asymptomatic carotid atherosclerotic plaque.  Stroke . 2001;  32 855-860
• 101 Gaydos C A, Summersgill J T, Sahne N N, Ramirez J S, Quinn T. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells.  Infect Immun . 1996;  64 1614-1620
• 102 Beatty W L, Byrne G I, Morrison R P. Repeated and persistent infection with Chlamydia and the development of chronic inflammation and disease.  Trends Microbiol . 1994;  2 94-98
• 103 Kol A, Sukhova G K, Lichtman A H, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression.  Circulation . 1998;  98 300-307
• 104 Rothermel C D, Schachter J, Lavrich P, Lipsitz E C, Francus T. Chlamydia trachomatis-induced production of interleukin-1 by human monocytes.  Infect Immun . 1989;  57 2705-2711
• 105 Kalayoglu M V, Hoerneman B, LaVerda D, Morrison S G, Morrison R P, Byrne G I. Cellular oxidation of low density lipoprotein by Chlamydia pneumoniae J Infect Dis .  1999;  180 780-790
• 106 Kalayoglu M V, Byrne B I. Induction of macrophage foam cell formation by Chlamydia pneumoniae J Infect Dis .  1998;  177 725-729
• 107 Papanicolaou D A, Wilder R L, Manolagas S C, Chrousos G P. The pathophysiologic roles of interleukin-6 in human disease.  Ann Intern Med . 1998;  128 127-137
• 108 Watkins N G, Hadlow W J, Moos A B, Caldwell H D. Ocular delayed hypersensitivity: apathogenetic mechanism of chlamydial conjunctivitis in guinea pigs.  Proc Natl Acad Sci USA . 1986;  83 7480-7487
• 109 Morrison R P, Belland R J, Lyng K, Caldwell H D. Chlamydial disease pathogenesis.  the 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med . 1989;  170 1271-1283
• 110 Laitinen K, Aluria A, Pyhala L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits.  Infect Immun . 1997;  65 4832-4835
• 111 Fong I W, Chiu B, Viira E, Fong M W, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection.  J Clin Microbiol . 1997;  35 48-52
• 112 Moazed T C, Campbell L A, Rosenfeld M E, Grayston J T, Kuo C C. Chlamydia pneumoniae accelerates the progression of atherosclerosis in apolipoprotein E deficient mice.  J Infect Dis . 1999;  180 238-241
• 113 Meier C R, Derby L E, Jick S S, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction.  JAMA . 1999;  281 427-431
• 114 Anderson J L, Muhlestein J B, Carlquist J. et al . Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study.  Circulation . 1999;  99 1540-1547
• 115 Veldhyuzen van Zanten J O S, Sherman P M. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systemic overview.  Can Med Assoc J . 1994;  150 177-185
• 116 Sipponen P, Seppala K, Aarynen M, Helske T, Kettunen P. Chronic gastritis and gastroduodenal ulcer: a case control study on risk of coexisting duodenal or gastric ulcer in patients with gastritis.  Gut . 1989;  30 922-929
• 117 Cullen D JE, Collins B J, Christiansen K J, Epis J, Warren J R, Cullen K J. Long term risk of peptic ulcer disease in people with Helicobacter pylori infection: a community-based study.  Gastroenterology . 1993;  104 A60
• 118 Koenig W, Rothenbacher D, Hoffmeister A. et al . Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease.  Circulation . 1999;  100 2326-2331
• 119 Strandberg T E, Tilvis R S, Vuoristo M, Lindroos M, Kosunen T U. Prospective study of Helicobacter pylori seropositivity and cardiovascular diseases in a general elderly population.  BMJ . 1997;  314 317-318
• 120 Wald N J, Law M R, Morris J K, Bagnall A M. Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study.  BMJ . 1997;  315 1199-1201
• 121 Folsom A R, Nieto J F, Sorlie P, Chambless L E, Graham D Y. for the Atherosclerosis Risk in Communities (ARIC) Study InvestigatorsHelicobacter pylori seropositivity and coronary heart disease incidence.  Circulation . 1998;  98 845-850
• 122 Strachan D P, Mendall M A, Carrington D. et al . Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the Caerphilly Prospective Heart Disease Study.  Circulation . 1998;  98 1286-1290
• 123 Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies.  BMJ . 1998;  316 1130-1132
• 124 Pasceri V, Cammarota G, Patti G. et al . Association of virulent Helicobacter pylori strains with ischemic heart disease.  Circulation . 1998;  97 1675-1679
• 125 Peek R M, Miller G, Tham K T. et al . Heightened inflammatory response and cytokine expression in vivo to CagA+ Helicobacter pylori strains.  Lab Invest . 1995;  71 760-70
• 126 Williams R C. Periodontal disease.  N Engl J Med . 1990;  322 373-382
• 127 Brown L J, Brunelle J A, Kingman A. Periodontal status in the United States, 1988-9: prevalence, extent, and demographic variation.  J Dent Res . 1996;  75 672-683
• 128 Beck J D, Koch G G, Rozier R G, Tudor G E. Prevalence and risk indicators for periodontal attachment loss in a population of old community-dwelling blacks and whites.  J Periodontol . 1991;  61 521-528
• 129 Alpagot T, Wolff L F, Smith Q T, Tran S D. Risk indicators for periodontal disease in a racially diverse urban population.  J Clin Periodontol . 1996;  23 982-988
• 130 Wu T, Trevisan M, Genco R J, Dorn J P, Falkner K L, Sempos C T. Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study.  Arch Intern Med . 2000;  160 2749-2755
• 131 Hujoel P P, Drangsholt M, Spiekerman C, DeRouen T A. Periodontal disease and coronary heart disease risk.  JAMA . 2000;  284 1406-1410
• 132 Worrall B B, DeGraba T J. The genetics of cerebrovascular atherosclerosis.  Seminars in Cerebrovascular Diseases and Stroke . 2002;  2 14-23
• 133 Liao D, Myers R, Hunt S. et al . Family history of stroke and stroke risk. The Family Heart Study.  Stroke . 1997;  28 1908-1912
• 134 Kiely D K, Wolf P A, Cupples L A, Beiser A S, Kannel W B. Familial aggregation of stroke: The Framingham Study.  Stroke . 1993;  24 1366-1371
• 135 Joutel A, Corpechot C, Ducros A. et al . Notch 3 mutation in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a mendelian condition causing stroke and vascular dementia.  Ann NY Acad Sci . 1997;  826 213-217
• 136 Tjernstrom F, Hellmer G, Nived O, Truedsson L, Sturfelt G. Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus.  Lupus . 1999;  8 103-108
• 137 Schrijver H M, Crusius J B, Uitdehaag B M. et al . Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS.  Neurology . 1999;  52 595-599
• 138 Bioque G, Crusius J B, Koutroubakis I. et al . Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease.  Clin Exp Immunol . 1995;  102 379-383
• 139 Francis S E, Camp N J, Dewberry R M. et al . Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease [see comments].  Circulation . 1999;  99 861-866
• 140 Iacoviello L, Donati M B, Gattone M. Possible different involvement of interleukin-1 receptor antagonist gene polymorphism in coronary single vessel disease and myocardial infarction [letter; comment].  Circulation . 2000;  101 E193
• 141 Kokkotou E, Philippon V, Gueye-Ndiaye A. et al . Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in West Africa.  J Hum Virol . 1998;  1 469-474
• 142 Taylor M L, Perez-Mejia A, Yamamoto-Furusho J K. et al . Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the state of Guerrero, Mexico.  Mycopathologia . 1997;  138 137-142
• 143 Momiyama Y, Hirano R, Taniguchi H, Nakamura H, Ohsuzu F. The effects of interleukin-1 gene polymorphisms on the development of coronary artery disease associated with Chlamydia pneumoniae infection.  J Am Coll Cardiol . 2001;  38 712-717
• 144 Inoue M, Itoh H, Ueda M. et al . Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance in VEGF in progression of atherosclerosis.  Circulation . 1998;  98 2108-2116
• 145 Schaper W, Buschmann I. VEGF and therapeutic opportunities in cardiovascular disease.  Curr Opin Biotechnol . 1999;  10 541-543
• 146 Simons M, Bonow R O, Chronos N A. et al . Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary.  Circulation . 2000;  102 E73-86
• 147 Yuan C, Kerwin W S, Ferguson M S, Polissar N, Zhang S, Cai J, Hatsukami T S. Contrast enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization.  J Magn Reson Imaging . 2002;  15 62-67
• 148 Quick H H, Debatin J F, Ladd M E. MR imaging of the vessel wall.  Eur Radiol . 2002;  12 889-900
• 149 Yuan C, Zhang S X, Polissar N L. et al . Identification of fibrous cap rupture with magnetic resonance imaging is highly associated with recent transient ischemic attack or stroke.  Circulation . 2002;  105 181-185
• 150 Weiss C R, Arai A E, Bui M N. et al . Arterial wall MRI characteristics are associated with elevated serum markers of inflammation in humans.  J Mag Reson Imaging . 2001;  14 698-704
• 151 Schmitz S A, Taupitz M, Wagner S, Wolf K J, Beyersdorff D, Hamm B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles.  J Mag Reson Imaging . 2001;  14 355-361